Drugs / Flublok Quadrivalent
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03658629 | Sep 2018 → Apr 2019 | influenza | Novavax | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03460743 | Mar 2018 → Oct 2019 | influenza | Laboratorios Liomont | Completed | No outcome recorded |
| Phase 3 | NCT02290509 | Oct 2014 → May 2015 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05518500 | Aug 2022 → Dec 2026 expected | premature aging syndrome | The Jackson Laboratory | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05514002 Comparator | Sep 2022 → Dec 2023 | influenza | Fatimah Dawood | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-11-18 | Sanofi | Regulatory European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗
The European Commission has granted a marketing authorization for Supemtek ® , a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older. |
| 2020-09-22 | Sanofi | Regulatory CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Supemtek® (recombinant influenza vaccine) for active immunization for the prevention of influenza in adults. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flublok Quadrivalent | “Flublok Quadrivalent® (Quadrivalent Recombinant Influenza Vaccine, Seasonal Formulation)” NCT03460743 ↗6“Sponsor Product Identifiers Flublok® Quadrivalent of Laboratories Liomont, S.A. de C.V.” NCT03460743 ↗ “a single dose of RIV (Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain)” NCT05514002 ↗ “Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.” NCT05518500 ↗ |
| Modality | Vaccine | “A new quadrivalent recombinant influenza vaccine (RIV4)” PMID 28968871 ↗ Dec 2017 |
| Route | Intramuscular | “Intramuscular injection of vaccine containing 4 x 45µg (180µg total)” NCT02290509 ↗ |